New test may improve the ability to diagnose riskiest forms
Ninety-nine percent of cervical cancers are caused by human papillomavirus (HPV). More than 200 HPVs, some of which are associated with varying degrees of cancer risk, complicate diagnosis and treatment. A report in The Journal of Molecular Diagnostics, published by Elsevier, describes a new "two-for-one" diagnostic approach that not only detects the type of HPV infection, but also indicates precancerous markers. This test may improve the ability to diagnose the riskiest forms of HPV infection, provide rapid results at low cost, and help avoid unnecessary diagnostic procedures.

In this proof-of-concept study, HPV RNA-Seq was used to analyze samples in 55 patients, 28 with low-grade squamous intraepithelial lesions (LSIL) and 27 patients with precancerous HSIL.

HPV RNA-Seq was able to detect and determine the type of HPV infection among a panel of 16 high-risk HPVs with results comparable to a widely used and officially approved HPV DNA molecular diagnostic kit. In fact, HPV RNA-Seq detected two more HPV-positive patients than the DNA test and also identified more patients with multiple HPV infections.

The test was found to have sensitivity (ability to detect the presence of an HPV) of 97.3 percent and negative predictive value of 93.8 percent. "Effective cervical cancer screening requires high sensitivity and NPV for high-risk HPV infection, since women with a negative HPV test are usually tested again only after several years," noted Prof. Eloit, Lead investigator, Pathogen Discovery Laboratory.

Prof. Eloit suggests that the use of HPV RNA-Seq in certain patients can help eliminate unnecessary colposcopies. The test may also be applicable for other HPV-associated cancers such as anal cancer and head and neck cancer.

Source: https://www.news-medical.net/news/20190812/New-test-may-improve-the-ability-to-diagnose-riskiest-forms-of-HPV-infection.aspx
B●●●●●●t J●●a and 2 other likes this1 share
Like
Comment
Share